Pediatric hematology-oncology, stem cell transplantation and veno-occlusive disease

Born on August 26, 1964

Professional Career

August 2002	-	Ongoing	Assistant Professor, Department of Hematology, Oncology, Immunology und Stem Cell Transplantation, University Children's Hospital Ulm, Germany
July 2000	-	June 2002	Assistant Professor, Department of Hematology, Oncology, Immunology und Stem Cell Transplantation, University Children's Hospital Zürich, Switzerland
July 1997	-	June 2000	Fellowship in Pediatric Hematology und Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
July 1994	-	June 1997	Residency in Pediatrics at New York University (NYU, Bellevue and Tisch Hospital, New York, NY)
July 1992	-	June 1994	Research fellow, Pediatric Hematology and Oncology
October 1990	-	June 1992	Residency in Pediatrics, University of Hannover Medical School, Hannover Germany

Qualifications

• European board certified in Pediatrics: 2003 (Facharzt)
• US board eligible for Pediatric Hematology and Oncology: 2000
• US board certified in Pediatrics: 1997 (Facharzt)

Memberships

• AACR Member since 2004
• EHA Member since 2003
• ASH Member since 2002
• EBMT Member since 2000

Scientific Career

December 2003	-	present	Principal investigator: Prospective, multi-center, international study of the incidence and outcome of veno-occlusive disease (VOD) with the prophylactic use of Defibrotide (DF, Gentium, Italy) in pediatric stem cell transplantation
August 2002	-	present	Molecular analysis of kit mutations in malignant hematopoietic diseases
Juli 1998	-	June 2000	Generation and analysis of a c-kit (stem cell factor receptor) ‚knock-in' mouse model, in the laboratory of Prof. Dr. Peter Besmer at Memorial Sloan?Kettering Cancer Center; New York, USA
April 1992	-	Juni 1994	Study of angiogenesis as an anti-tumor tool in a murine glioblastoma multiforme modell in the lab of Prof. Karl Welte
Mai 1986	-	Januar 1988	Photodynamic therapy of malignant melanoma, Technical University Munich, in the lab of Prof. Gerhard Herzog

Grants and Awards

2006 In vivo mouse models of molecular targeted therapies. Novartis, Nürnberg, Germany

2005 Prospective evaluation of novel therapeutic modalities in subgroups of childhood AML within the AML-BFM stuy 2004', Novartis, Nürnberg, Germany.

2005 ‘Murine HSCT modells in order to evaluate the leukemogenic relevance, treatment options and mechanisms of resistance of kit ITD mutations in childhood AML', Schickedanz Foundation, Fürth, Germany

2004 ‘Complex kit ITD mutations in childhood AML, prospective evaluation of children enrolled in the AML-BFM stuy 2004', Novartis, Nürnberg, Germany

2001 Mutational analysis of the stem cell factor receptor ‚c-ki't in a Murine ‚knock-in' modell, Huggenberger-Bischoff Foundation, Zurich, Switzerland'

1992 ‘The angiogenic effect of G-CSF and IL-1 in a murine in vivo model and the receptor expression on endothelial cells in vitro' ‘Freundesgesellschaft der Medizinischen Hochschule Hannover'.

Publications

Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006;38:547-553.

Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-kit receptor tyrosine kinase ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood. 2006.( prepublished online July 13, 2006)

Agosti V, Corbacioglu S*, , Ehlers I, Waskow C, Sommer G, Berrozpe G, Tucker CM, Manova K, Moore MAS, Rodewald HR, and Besmer P: Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro-T and pro-B cell development; Journal of Experimental Medicine, 2004;199:867-878 (Co-Firstauthorship)

Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, Strahm B, Gross-Wieltsch U, Sykora KW, Ridolfi-Lüthy A, Basu O, Gruhn B, Güngör T, Mihatsch W, and Schulz AS: Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multi-centre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant, 2004;33:189-195.

Corbacioglu S and Schulz AS: Die Lebervenenverschlusserkrankung im Kindesalter (Hepatic veno-occlusive disease in children); Monatsschrift Kinderheilkunde, Feb. 2003

Corbacioglu S, Eber S, Gungor T, Hummerjohann J, and Niggli F: Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. Journal of Pediatric Hematology and Oncology, 2003;25:327-329.

Corbacioglu S, Bux J, König A, Gabrilove JL, Welte K, and Bussel JB: Serum Granulocyte Colony-Stimulating Factor Levels are not increased in Patients with Autoimmune Neutropenia of Infancy. Journal of Pediatrics: 137; (1) 96-99, 2000

Corbacioglu S, Dhodapkar K, Chang M, Karpatkin M, and DiMicheli D: Purpura fulminans due to Group A beta hemolytic streptococcus sepsis: Report of two cases and review of treatment options. Journal of Pediatrics 137, (4) 562-567, 2000

Corbacioglu S, Welte K, and Pietsch T: Is granulocyte colony-stimulating factor an angiogenic factor in human gliolastoma? In: Cytokines in Hematology, Oncology, and Immunology III Eds.: Freund, M., Schmidt, R.E., Welte, K., Springer-Verlag, pp 401-410, 1994

Corbacioglu S, Pietsch T, König A, and Welte K: Angiogenesis in an in vivo model of human glioblastoma: effects of anti-G-CSF antibodies, Dexamethasone and IL-1 receptor antagonist, European Journal of Pediatrics, Vol. 153, 215, 1994

Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu S, Jürgens H, Dworzak M, Kaspers G, Creutzig U, and Zwaan CM: Gemtuzumab ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia. Onkologie, 2004;27:269-272.

Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR, and Besmer P: Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2003;100:6706-6711.

Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, and Kaspers GJ: Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 2003;101:3868-3871.

Güngör T, Corbacioglu S, Storb R, and Seger R: Non-myeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenital. Bone Marrow Transplant, 2003;31:407-410.

König A, Corbacioglu S, Ballmaier M, and Welte K: Downregulation of c-kit expression in human endothelial by inflammatory stimuli. Blood, 90:148-155, 1997.

Stolze B, Emmendörffer A, Corbacioglu S, König A, Welte K, and Ebell W: Effects of bone marrow fibroblasts on the proliferation and maturation of myeloid leukemic cell lines. Exp. Hematol, 23:1378-1387, 1995.

Koenig A, Yakisan E, Reuter M, Huang M, Sykora KW, Corbacioglu S, and Welte K: Differential regulation of stem cell factor mRNA expression in human endothelial cells by bacterial pathogens: An in vitro model of inflammation. Blood, 83:2836-2843, 1994.

Oez S, Birkmann J, Smetak M, Corbacioglu S, Hoffmann-Wackersreuther G, Welte K, and Gallmeier WM: Regulation of the density of the stem cell factor receptor (c-kit) by tumor necrosis factor alpha on a human myeloid cell line. European Cytokine Network, 4 (4):293-297, 1993.

Herzog M, Horch HH, Enders S, Schroder E, and Corbacioglu S: Experimental studies on photodynamic therapy of malignant melanoma. Fortschr Kiefer Gesichtschir, 33:166-168, 1988.